Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a fast-growing cancer of the blood and bone marrow that results in the rapid increase of abnormal white blood cells, which can interfere with normal blood cell production.
NPM1-Mutated Acute Myeloid Leukemia: Eltanexor Study
We are evaluating a new drug called eltanexor for patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The study aims to see if it is safe and effective in treating this condition.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 60 years old?
- Do you have a documented diagnosis of relapsed or refractory NPM1-mutated AML (a type of blood cancer)?
- Have you had any major surgery in the last 4 weeks?
- Do you have any serious heart problems, like unstable angina or heart failure?
- Are you currently taking any medications that could interfere with the study, like blood thinners or certain cancer treatments?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Eltanexor
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Azienda Ospedaliero Universitaria Delle Marche
Clinica di Ematologia
Ancona, Italy
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
Divisione di ematologia
Canalicchio, Italy
University Hospital Of Perugia
Ematologia
Chiugiana-La Commenda, Italy
Sponsor: Azienda Ospedaliero Universitaria Delle Marche
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.